Auro Laboratories re-appoints Kiran Kulkarni as Whole Time Director for 3 years

Auro Laboratories Limited has approved the re-appointment of Mr. Kiran Suresh Kulkarni as Whole Time Director for a term of three years, effective from May 24, 2027, to May 23, 2030. The decision, taken at a board meeting on June 30, 2026, is based on the recommendations of the Nomination and Remuneration Committee and is subject to the approval of shareholders at the ensuing Annual General Meeting. The re-appointment ensures continuity in leadership as the current term of Mr. Kulkarni expires on May 23, 2027.

The Board of Directors met on June 30, 2026, to transact business including the re-appointment. Mr. Kulkarni is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other such authority. The company has disclosed the necessary details in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

37th Annual General Meeting

The Notice convening the 37th Annual General Meeting of the Company has been scheduled for Tuesday, August 11, 2026. The meeting will be held through Video-Conferencing ("VC") and Other Audio-Visual Means ("OAVM"). Shareholders will vote on the resolution to re-appoint Mr. Kulkarni during this meeting.

Director Profile

Mr. Kiran Suresh Kulkarni brings over 25 years of experience in the QC/QA department of API manufacturing companies. He currently oversees the quality control and general management functions at the manufacturing facility of the Company.

Particulars	Details
Name of the Director	Mr. Kiran Suresh Kulkarni
Reason for Change	Re-Appointment
Date of Appointment	May 24, 2027
Term of Appointment	Three (3) Years (May 24, 2027 to May 23, 2030)
Brief Profile	Over 25 years of experience in QC/QA department of API manufacturing companies. Looks after quality control and general management functions.
Disclosures of Relationships	Not Applicable
Regulatory Status	Not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.32%	-2.75%	-2.07%	+13.42%	-5.79%	+33.30%

Auro Laboratories Limited announced that Mr. Kuntal Pancholi has resigned from the position of Chief Financial Officer (CFO) and Key Managerial Personnel effective immediately. The resignation, effective from the close of business hours on May 28, 2026, was attributed to personal reasons with no other material cause cited. This change impacts the company's senior management structure as per the provisions of Section 203 of the Companies Act, 2013.

The company confirmed that Mr. Kuntal Pancholi ceased to be a Key Managerial Personnel from May 28, 2026. In a disclosure to the stock exchanges, the company stated that there is no other material reason for the resignation beyond those mentioned in the resignation letter. The resignation was accepted by the Board of Directors of Auro Laboratories Limited.

Regulatory Disclosure

The filing was made to BSE Limited under Regulation 30 of the SEBI (LODR) Regulations, 2015. The disclosure references SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company provided the required details in Annexure A, confirming that the resignation letter is attached and there are no other material relationships to disclose.

Resignation Details

Particulars	Details
Name	Mr. Kuntal Pancholi
Designation	Chief Financial Officer & Key Managerial Personnel
Reason for Resignation	Personal reasons
Effective Date	May 28, 2026

The resignation letter submitted by Mr. Kuntal Pancholi explicitly stated that there are no other material reasons for his departure. He expressed gratitude for the trust and support received during his tenure and wished the company continued success. The communication was signed by Siddhartha Deorah, Whole Time Director of Auro Laboratories Limited.